caa a22 4500 445335165 CHVBK 20180317142752.0 cr unu---uuuuu 170323e20110301xx s 000 0 eng 10.1245/s10434-010-1128-7 doi (NATIONALLICENCE)springer-10.1245/s10434-010-1128-7 Correlation Between gp96 Expression and the Surgical Outcome in Patients With Esophageal Squamous Cell Carcinoma [Elektronische Daten] [Yasunori Akutsu, Hisahiro Matsubara, Masayuki Kano, Akihiro Usui, Yasuo Yoneyama, Norimasa Ikeda, Aki Komatsu, Gulbostan Yusup] Background: Heat-shock protein gp96 plays an important role in antitumor immunoreactions. Gp96 has a close relationship with antitumor immunity. This study evaluated the correlation between gp96 expression and the prognosis in esophageal squamous cell carcinoma. Methods: Seventy-eight patients with primarily resected esophageal squamous cell carcinoma were enrolled onto this study, and gp96 expression was evaluated by immunohistochemical staining. The association of clinicopathological factors and patients' survival was calculated by univariate (log rank test) and multivariate (Cox proportional hazard regression method) analyses. Results: Fifty-seven (73%) of 78 cases were gp96 positive, and 21 were negative (27%). The survival of patients with gp96-negative disease was significantly shorter (5-year survival, 22.9months) than with gp96-positive disease (45.8months; P=0.049), and the multivariate analysis showed that gp96 negativity is an independent risk factor for poor survival (hazard ratio, 2.577; P=0.040). Gp96-negative cases had more metastatic lymph nodes than did negative cases, especially in T1 cases (4.8 in gp96-negative cases vs. 0.84 in gp96-positive cases; P=0.064) Conclusions: The downregulation of gp96 expression is closely correlated with poor survival in esophageal squamous cell carcinoma. Society of Surgical Oncology, 2010 Akutsu Yasunori Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan aut Matsubara Hisahiro Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan aut Kano Masayuki Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan aut Usui Akihiro Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan aut Yoneyama Yasuo Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan aut Ikeda Norimasa Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan aut Komatsu Aki Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan aut Yusup Gulbostan Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan aut Annals of Surgical Oncology Springer-Verlag 18/3(2011-03-01), 832-837 1068-9265 18:3<832 2011 18 10434 https://doi.org/10.1245/s10434-010-1128-7 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1245/s10434-010-1128-7 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Akutsu Yasunori Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan aut NATIONALLICENCE 700 1- Matsubara Hisahiro Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan aut NATIONALLICENCE 700 1- Kano Masayuki Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan aut NATIONALLICENCE 700 1- Usui Akihiro Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan aut NATIONALLICENCE 700 1- Yoneyama Yasuo Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan aut NATIONALLICENCE 700 1- Ikeda Norimasa Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan aut NATIONALLICENCE 700 1- Komatsu Aki Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan aut NATIONALLICENCE 700 1- Yusup Gulbostan Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan aut NATIONALLICENCE 773 0- Annals of Surgical Oncology Springer-Verlag 18/3(2011-03-01), 832-837 1068-9265 18:3<832 2011 18 10434 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer